Cargando…
Favipiravir, an anti-influenza drug against life-threatening RNA virus infections
Favipiravir has been developed as an anti-influenza drug and licensed as an anti-influenza drug in Japan. Additionally, favipiravir is being stockpiled for 2 million people as a countermeasure for novel influenza strains. This drug functions as a chain terminator at the site of incorporation of the...
Autores principales: | Shiraki, Kimiyasu, Daikoku, Tohru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102570/ https://www.ncbi.nlm.nih.gov/pubmed/32097670 http://dx.doi.org/10.1016/j.pharmthera.2020.107512 |
Ejemplares similares
-
Detection of cytomegalovirus in an immunocompetent adult presenting with acute retinal necrosis due to varicella-zoster virus: a case report
por: Nakamura, Tomoko, et al.
Publicado: (2015) -
Herpes Zoster and Recurrent Herpes Zoster
por: Shiraki, Kimiyasu, et al.
Publicado: (2017) -
T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections
por: Furuta, Yousuke, et al.
Publicado: (2009) -
Antiviral therapy for COVID-19: Derivation of optimal strategy based on past antiviral and favipiravir experiences
por: Shiraki, Kimiyasu, et al.
Publicado: (2022) -
Preliminary investigation of drug impurities associated with the anti-influenza drug Favipiravir – An insilico approach
por: Anil Kumar, S., et al.
Publicado: (2021)